Cite
HARVARD Citation
Miles, D. et al. (n.d.). 1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). European journal of cancer. pp. S271-. [Online].